Immunic And 2 Other Stocks Under $2 Insiders Are Buying
Portfolio Pulse from Avi Kapoor
Insiders at OPKO Health, Immunic, and Fresh Tracks Therapeutics have recently made significant stock purchases, signaling potential confidence in their companies' futures. OPKO Health and Immunic both reported positive financial news, while Fresh Tracks Therapeutics experienced a stock price decline over the past month.
February 29, 2024 | 3:40 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Fresh Tracks Therapeutics saw a 10% owner buy 20,109 shares at $0.90 each amid a 6% stock decline over the past month.
The insider purchase at Fresh Tracks Therapeutics, despite a recent decline in stock price, suggests a belief in the company's recovery or undervaluation. However, without positive news to counter the decline, the short-term impact is uncertain.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Immunic's CEO acquired 14,000 shares at $1.31 each after reporting a narrower-than-expected Q4 loss.
The insider purchase by Immunic's CEO, following a report of a narrower-than-expected quarterly loss, indicates a positive outlook from the company's leadership, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90
POSITIVE IMPACT
OPKO Health saw insider buying of 500,000 shares at $0.99 each, following upbeat quarterly results.
The insider purchase at OPKO Health, combined with recent positive quarterly results, suggests a strong vote of confidence in the company's future prospects, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90